search
Back to results

Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping (PROCEEDING)

Primary Purpose

Postpartum Hemorrhage

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery
Initiation of standard postpartum oxytocin immediately following placenta delivery
Saline Placebo
Saline Placebo
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Postpartum Hemorrhage

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • All laboring women (induced, augmented, or spontaneous) at term admitted to Labor and Delivery while comfortable
  • Scheduled cesareans
  • Women aged 18 years or older
  • Admitted at NewYork-Presbyterian Morgan Stanley Children's Hospital (CHONY) or Allen Pavilion Labor and Delivery units

Exclusion Criteria:

  • Multifetal gestation
  • Placental abruption or antepartum hemorrhage
  • Maternal bleeding disorder
  • Known fetal anomaly or anemia
  • Fetal growth restriction with abnormal Doppler
  • Significant maternal anemia (pre-operative hemoglobin ≤ 7g/dL
  • Intrapartum stillbirth
  • Placenta accreta spectrum
  • Abnormal placentation (previa or abruption)
  • Planned cord blood banking
  • Refusal of blood products
  • Any contraindication for delayed cord clamping
  • Maternal history of aortic stenosis or pulmonary hypertension or other severe cardiac structural disease

Sites / Locations

  • Columbia University Irving Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Pre-placental group

Post-placental group

Arm Description

Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our "intervention" group. Saline placebo will be initiated post placenta delivery (within 15 seconds).

Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).

Outcomes

Primary Outcome Measures

Change in Hemoglobin
Change defined as greater or equal to 1.0 g/dL (≥ 1 standard deviation (SD)) hemoglobin drop between the two arms following a vaginal delivery and greater or equal to 0.9 g/dL (≥ 1SD) following a cesarean delivery.

Secondary Outcome Measures

Cumulative Maternal Adverse Outcomes
Any adverse maternal outcome (adverse event) including blood transfusion or symptomatic anemia.
Cumulative Neonatal Adverse Outcomes
Any adverse neonatal outcome (adverse event) including jaundice, hematocrit laboratory abnormality.

Full Information

First Posted
November 14, 2020
Last Updated
December 28, 2021
Sponsor
Columbia University
search

1. Study Identification

Unique Protocol Identification Number
NCT04632264
Brief Title
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
Acronym
PROCEEDING
Official Title
Optimal Timing of Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping - PROCEEDING (PostpaRtum OxytoCin Era dElayed corD clampING) Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
December 10, 2020 (Actual)
Primary Completion Date
April 2, 2021 (Actual)
Study Completion Date
September 16, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Columbia University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Increased blood loss after vaginal or cesarean delivery is one of the top causes of maternal complications. Oxytocin is a common medication given to mothers by IV or an injection to limit the amount of blood loss after delivery. The investigators do not know the best time after delivery that oxytocin should be given. This research is being done to find out if starting the medication oxytocin right after the baby is born or after the placenta comes out decreases the amount of blood lost after birth when we delay cord clamping after birth.
Detailed Description
The optimal timing of prophylactic oxytocin administration on both maternal and neonatal outcomes has not been definitively established with delayed cord clamping. Maternal considerations include the risk of postpartum hemorrhage, need for additional uterotonic medications, need for maternal transfusion, retained placenta, and postpartum drop in hemoglobin. Neonatal considerations include markers of neonatal well-being such as arterial pH and 5-minute Apgar score, as well as hemoglobin and bilirubin levels. There is currently no protocol on the timing of third stage prophylactic oxytocin and its administration is based on physician/ delivery provider's preference. The investigators propose a quality assessment initiative, through a randomized controlled trial designed to compare the blood loss between administrations of prophylactic oxytocin immediately after delivery of the neonate versus after delivery of the placenta with delayed cord clamping.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Hemorrhage

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two parallel randomized, placebo-controlled, and double-blinded studies. For this study we will include 52 scheduled cesarean sections and 52 vaginal deliveries as two separate cohorts.
Masking
ParticipantCare Provider
Masking Description
Randomization will be achieved using a computer generated algorithm. Both patient and provider will be unaware of the allocation arm.
Allocation
Randomized
Enrollment
104 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pre-placental group
Arm Type
Experimental
Arm Description
Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our "intervention" group. Saline placebo will be initiated post placenta delivery (within 15 seconds).
Arm Title
Post-placental group
Arm Type
Other
Arm Description
Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).
Intervention Type
Other
Intervention Name(s)
Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery
Intervention Description
The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
Intervention Type
Other
Intervention Name(s)
Initiation of standard postpartum oxytocin immediately following placenta delivery
Intervention Description
Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
Intervention Type
Other
Intervention Name(s)
Saline Placebo
Intervention Description
Saline placebo will be initiated post placenta delivery (within 15 seconds).
Intervention Type
Other
Intervention Name(s)
Saline Placebo
Intervention Description
Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
Primary Outcome Measure Information:
Title
Change in Hemoglobin
Description
Change defined as greater or equal to 1.0 g/dL (≥ 1 standard deviation (SD)) hemoglobin drop between the two arms following a vaginal delivery and greater or equal to 0.9 g/dL (≥ 1SD) following a cesarean delivery.
Time Frame
Up to 24 hours
Secondary Outcome Measure Information:
Title
Cumulative Maternal Adverse Outcomes
Description
Any adverse maternal outcome (adverse event) including blood transfusion or symptomatic anemia.
Time Frame
Postpartum, Up to 6 weeks
Title
Cumulative Neonatal Adverse Outcomes
Description
Any adverse neonatal outcome (adverse event) including jaundice, hematocrit laboratory abnormality.
Time Frame
Post Delivery, Up to 6 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All laboring women (induced, augmented, or spontaneous) at term admitted to Labor and Delivery while comfortable Scheduled cesareans Women aged 18 years or older Admitted at NewYork-Presbyterian Morgan Stanley Children's Hospital (CHONY) or Allen Pavilion Labor and Delivery units Exclusion Criteria: Multifetal gestation Placental abruption or antepartum hemorrhage Maternal bleeding disorder Known fetal anomaly or anemia Fetal growth restriction with abnormal Doppler Significant maternal anemia (pre-operative hemoglobin ≤ 7g/dL Intrapartum stillbirth Placenta accreta spectrum Abnormal placentation (previa or abruption) Planned cord blood banking Refusal of blood products Any contraindication for delayed cord clamping Maternal history of aortic stenosis or pulmonary hypertension or other severe cardiac structural disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephanie E. Purish, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Irving Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23843134
Citation
McDonald SJ, Middleton P, Dowswell T, Morris PS. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev. 2013 Jul 11;2013(7):CD004074. doi: 10.1002/14651858.CD004074.pub3.
Results Reference
background
PubMed Identifier
20687079
Citation
Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD006173. doi: 10.1002/14651858.CD006173.pub2.
Results Reference
background
PubMed Identifier
27733286
Citation
GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. Erratum In: Lancet. 2017 Jan 7;389(10064):e1.
Results Reference
background
PubMed Identifier
30278462
Citation
Rana N, Kc A, Malqvist M, Subedi K, Andersson O. Effect of Delayed Cord Clamping of Term Babies on Neurodevelopment at 12 Months: A Randomized Controlled Trial. Neonatology. 2019;115(1):36-42. doi: 10.1159/000491994. Epub 2018 Oct 2.
Results Reference
background
PubMed Identifier
26010418
Citation
Andersson O, Lindquist B, Lindgren M, Stjernqvist K, Domellof M, Hellstrom-Westas L. Effect of Delayed Cord Clamping on Neurodevelopment at 4 Years of Age: A Randomized Clinical Trial. JAMA Pediatr. 2015 Jul;169(7):631-8. doi: 10.1001/jamapediatrics.2015.0358.
Results Reference
background
PubMed Identifier
22089242
Citation
Andersson O, Hellstrom-Westas L, Andersson D, Domellof M. Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial. BMJ. 2011 Nov 15;343:d7157. doi: 10.1136/bmj.d7157.
Results Reference
background
PubMed Identifier
28002310
Citation
Committee Opinion No. 684: Delayed Umbilical Cord Clamping After Birth. Obstet Gynecol. 2017 Jan;129(1):1. doi: 10.1097/AOG.0000000000001860.
Results Reference
background
PubMed Identifier
31742629
Citation
Purisch SE, Ananth CV, Arditi B, Mauney L, Ajemian B, Heiderich A, Leone T, Gyamfi-Bannerman C. Effect of Delayed vs Immediate Umbilical Cord Clamping on Maternal Blood Loss in Term Cesarean Delivery: A Randomized Clinical Trial. JAMA. 2019 Nov 19;322(19):1869-1876. doi: 10.1001/jama.2019.15995.
Results Reference
background
PubMed Identifier
27732984
Citation
Hamm RF, Wang EY, Bastek JA, Srinivas SK. Assessing reVITALize: Should the Definition of Postpartum Hemorrhage Differ by Mode of Delivery? Am J Perinatol. 2017 Apr;34(5):503-507. doi: 10.1055/s-0036-1593535. Epub 2016 Oct 12.
Results Reference
background
PubMed Identifier
11641669
Citation
Jackson KW Jr, Allbert JR, Schemmer GK, Elliot M, Humphrey A, Taylor J. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol. 2001 Oct;185(4):873-7. doi: 10.1067/mob.2001.117363.
Results Reference
background

Learn more about this trial

Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping

We'll reach out to this number within 24 hrs